PITTSBURGH--(BUSINESS WIRE)--April 2, 2004--Mylan Laboratories Inc. (NYSE: MYL) announced that correspondence was submitted to the FDA today on its behalf with regard to its transdermal fentanyl product. Mylan's letter is a response to the March 31, 2004 letter submitted by Alza Corporation, a subsidiary of Johnson & Johnson. Copies of the correspondence have been filed with a Form 8-K and will be accessible on the SEC's website at www.sec.gov.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

    CONTACT: Mylan Laboratories Inc.
             Kris King, 724-514-1800

    SOURCE: Mylan Laboratories Inc.